Shanghai Pharmaceutical (02607) announced interim results. Net profit attributable to mother was about 3.504 billion yuan, a decrease of 21.4% year-on-year

According to the Zhitong Finance App, Shanghai Pharmaceutical (02607) announced its 2026 interim results, with operating income of about 147.47 billion yuan, up 4.15% year on year; net profit attributable to shareholders of listed companies was about 3,504 billion yuan, a decrease of 21.4% year on year; basic earnings per share were 0.95 yuan.

According to the announcement, the decrease in profit was mainly due to fluctuations in one-time special profit and loss. Net profit returned to mother after excluding one-time special profit and loss was 2,828 billion yuan, an increase of 1.65% over the previous year. Among them: the industrial sector contributed 1,343 billion yuan in profit, up 1.51% year on year; commercial sector contributed 1,794 billion yuan in profit, the same year on year; major participating companies contributed 78 million yuan in profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,477 billion yuan, up 17.98% year on year.